Trial
NCT03919175
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
TG Therapeutics
Condition
Lymphoma
Intervention
Umbralisib
Why stopped
Umbralisib development terminated; closed to accrual 8/29/2022
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-27